Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Developmental therapeutics

1455 - Safety and immunobiological activity of intratumoral (IT) double-stranded RNA (dsRNA) BO-112 in solid malignancies: first in human clinical trial

Date

09 Sep 2017

Session

Developmental therapeutics

Presenters

Ivan Marquez Rodas

Citation

Annals of Oncology (2017) 28 (suppl_5): v605-v649. 10.1093/annonc/mdx440

Authors

I. Marquez Rodas1, M.E. Rodriguez Ruiz2, S. Lopez-Tarruella Cobo1, J.L. Perez Gracia3, M. Ponz Sarvise3, R. Alvarez1, E. de Miguel4, Y. Jerez1, A. Calvo Ferrandiz1, M. Blanco Codesido1, J. Gayarre1, R. Ramos Medina1, A. Calles1, M.A. Aznar2, L. Planelles5, M. Quintero5, S. Martin Algarra3, M. Martin Jimenez1, I. Melero2

Author affiliations

  • 1 Medical Oncology, Hospital General Universitario Gregorio Marañon, Universidad Complutense, 28009 - Madrid/ES
  • 2 Cima, Universidad de Navarra, 31009 - Pamplona/ES
  • 3 Medical Oncology, Clinica Universidad de Navarra, Pamplona/ES
  • 4 Radiology, Hospital General Universitario Gregorio Marañon, Universidad Complutense, 28009 - Madrid/ES
  • 5 Bioncotech, Bioncotech, Valencia/ES
More

Resources

Abstract 1455

Background

BO-112 is a synthetic dsRNA formulated with a cationic carrier, polyethylenimine, which prevents its degradation by nucleases. In melanoma (MEL) mouse models, systemic administration of BO-112 activates MDA-5 and NOXA, leading to anti-tumoral activity connected to a sustained and extended expression of interferon (IFN) response genes. IT BO-112 delivery demonstrated in transplanted mouse models a safer and enhanced local and systemic antitumor effects. Final toxicity and biological profile of the first in human clinical trial that explores IT BO112 as an immune-modulatory treatment is presented (NCT02828098).

Methods

Patients (pts) with solid malignant tumors and metastases ≥1 cm accessible to IT injection were treated in 3 cohorts (C) in a 3 + 3 phase I design: C1: single IT BO-112 dose of 0.6 mg; C2: 1mg IT BO112 qw x 2-3 doses. C3: 0.6 mg IT BO112 qw x 2-3 doses. Pre & post treatment biopsies from the injected lesion were obtained, analysing necrosis, apoptosis, immune infiltrate and (first time reported for this trial) IFN-gamma mRNA expression (nanostring). PKs, cytokines and circulating immune cells (CICs) were studied in pre and post BO-112 blood samples.

Results

16 pts (12 more than the first report in ASCO 2017) were treated: 5 MEL, 3 sarcoma, 2 breast, 1 colorrectal, 1 neuroendocrine, 1 ovarian, 1 head & neck, 1 mesothelioma and 1 cystic adenoid. 50% pts had related AEs, being 94% G1-2 and 6% G3-4 (thrombocytopenia in 2 pts in C1 and C2, both considered DLT and recovered) BO112 was not detected in blood in any pts. Table summarizes the biological parameters that increase after BO112 treatment in tumor/blood samples.Table:

LBA20

TUMOR, N (%)BLOOD, N (%)
COHORT (N)NECROSIS- APOPTOSISCD8CD4IFN-gammaCICs
1 (6)4/5 (80)2/5 (40)4/5 (80)3/5 (60)6/6 (100)
2 (7)4/5 (80)2/5 (40)4/5 (80)1/1 (100)6/6 (100)
3 (3)3/3 (100)0/3 (0)0/2 (0)NA2/3 (67)

Conclusions

BO112 demonstrated a manageable safety profile. Its biological activity is consistent with both a direct antitumor effect and with intratumoral and systemic immunity activation, driven by IFN-gamma pathway. 1mg qw x 2-3 doses in combination with anti-PD-1 is the chosen regimen for an expansion cohort in pts refractory to anti-PD-1 therapy.

Clinical trial identification

NCT02828098 Release date: June 23, 2016

Legal entity responsible for the study

Bioncotech Theraputics

Funding

Bioncotech Theraputics

Disclosure

I. Marquez Rodas: Advisory role form BMS, MSD, Novartis, Roche, Pierre Fabre, Amgen and Bioncotech S. Lopez-Tarruella Cobo: Advisory Role (Novartis, Pfizer, Celgene) y Honoraria/lecturer (Novartis, Pfizer, AZ, Celgene, Roche) L. Planelles, M. Quintero: Bioncotech (employment) S. Martin Algarra: Advisory role for BMS, MSD, Novartis, Roche, Amgen I. Melero: Advisory role/consulting AstraZeneca; Bristol-Myers Squibb; Pfizer; Roche/Genentech All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.